Some female cancers may be genetic, meaning they are passed down from a parent through DNA (our genetic code or roadmap). In people with certain types of ovarian and uterine cancer, it may be helpful to test their DNA for any errors that can cause cancer. There are lots of important pieces of information to share when someone is diagnosed with cancer, and we are exploring a new way to share information. Patients with certain types of ovarian or uterine cancers will watch a short video that explains what genetic testing is and why it is so important. They will fill out a survey about what they think about the video and if the information is helpful.

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

This study seeks to promote clinical trial engagement in African Americans with pancreatic cancer. The first group of people will be interviewed by phone to discuss clinical trials. This information will be used to create a new mobile health app/website. In the second group, half of the participants will receive the new app and half will not. They will both be asked to complete questionnaires after their upcoming doctor visits.

You are being asked to participate in this research study because you have a type of tumor called a Central Nervous System (CNS) tumor, and you are scheduled to have surgery to remove this tumor. The study team wants to use left-over tumor samples from this surgery to study your tumor and test new ways to fight it.

This study is being done to answer the following question: Do two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating KS in PLWH in sub-Saharan Africa? We are doing this study because we want to find out if one of these approaches, PTX or PLD, is better than the other for KS. Both drugs may be given as part of the usual approach for your KS. The usual approach is defined as care most people get for KS.

This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.

The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).

The purpose of this study is to determine the safety of the addition of universal donor, expanded NK cells to gemcitabine/docetaxel for treatment of relapsed and refractory sarcomas.

Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades